Extended Data Table 1 Summary of response variables. Proportions of patients with objective response, clinical benefit, and durable response (> 6 months) as assessed by iRECIST. Confidence intervals for proportions were calculated using the Wilson score method. ORR, objective response rate; CBR, clinical benefit rate; DRR, durable response rate; PP, per-protocol population; FAS, full analysis set; PD-L1, programmed death-ligand 1

From: Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial